Lilly Confirms Date and Conference Call for First-Quarter 2024 Financial Results Announcement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P dip, trading choppy as tech stocks fall
- Brent hits lowest since before start of Iran war as more tankers exit Hormuz, easing supply
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Eli Lilly (LLY) sleep apnea study data seen as a win, stock gains
April 17, 2024 11:12 AM EDTEli Lilly & Co. (NYSE: LLY) announced positive topline results from its SURMOUNT-OSA Ph3 study on Wednesday, which evaluated tirzepatide compared to placebo in patients with obesity and sleep apnea.
According to the company, the phase 3 clinical trials that showed tirzepatide injection significantly reduced the... More
